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Abstract
α-Synuclein is a defining, key component of Lewy bodies and Lewy neurites in Parkinson’s disease (PD) and dementia
with Lewy bodies (DLB), as well as glial cytoplasmic inclusions in multiple system atrophy (MSA). The distribution and
spreading of these pathologies are closely correlated with disease progression. Recent studies have revealed that
intracerebral injection of synthetic α-synuclein fibrils or pathological α-synuclein prepared from DLB or MSA brains into
wild-type or transgenic animal brains induced prion-like propagation of phosphorylated α-synuclein pathology. The
common marmoset is a very small primate that is expected to be a useful model of human diseases. Here, we show
that intracerebral injection of synthetic α-synuclein fibrils into adult wild-type marmoset brains (caudate nucleus and/or
putamen) resulted in spreading of abundant α-synuclein pathologies, which were positive for various antibodies
to α-synuclein, including phospho Ser129-specific antibody, anti-ubiquitin and anti-p62 antibodies, at three months
after injection. Remarkably, robust Lewy body-like inclusions were formed in tyrosine hydroxylase (TH)-positive neurons
in these marmosets, strongly suggesting the retrograde spreading of abnormal α-synuclein from striatum to substantia
nigra. Moreover, a significant decrease in the numbers of TH-positive neurons was observed in the injection-side of the
brain, where α-synuclein inclusions were deposited. Furthermore, most of the α-synuclein inclusions were positive for
1-fluoro-2,5-bis (3-carboxy-4-hydroxystyryl) benzene (FSB) and thioflavin-S, which are dyes widely used to visualize the
presence of amyloid. Thus, injection of synthetic α-synuclein fibrils into brains of non-transgenic primates induced
PD-like α-synuclein pathologies within only 3 months after injection. Finally, we provide evidence indicating that
neurons with abnormal α-synuclein inclusions may be cleared by microglial cells. This is the first marmoset model
for α-synuclein propagation. It should be helpful in studies to elucidate mechanisms of disease progression and
in development and evaluation of disease-modifying drugs for α-synucleinopathies.
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Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disease after Alzheimer’s disease, and
Lewy bodies (LBs) and Lewy neurites (LNs) are character-
istic features of PD. Dementia with Lewy bodies (DLB) is
also a progressive neurodegenerative disease characterized
by the appearance of LBs and LNs in cortex [17, 22]. The
discovery of disease-associated mutation in the α-synuclein
gene SNCA and subsequent immunostaining studies with
antibodies demonstrated that α-synuclein is the major
component of LBs and LNs [2, 55, 56]. It is also the major
component of glial cytoplasmic inclusions (GCIs) in mul-
tiple system atrophy (MSA) [54, 58]. These diseases are
collectively referred to as α-synucleinopathies. To date, six
missense mutations in the SNCA gene and occurrence of
gene multiplication have been identified in familial forms
of PD and DLB [1, 5, 24, 28, 29, 41, 52, 62]. α-Synuclein is
a small protein of 140 amino acids, which is localized in
presynaptic termini, and is involved in maintenance of
synapses and synaptic plasticity. In PD, DLB, or MSA pa-
tients, it is deposited in the brain as a filamentous form
with cross-β structure [51], which is abnormally phos-
phorylated at Ser129 and partially ubiquitinated [15, 21].
α-Synuclein is natively unfolded, but readily assembles
into amyloid-like fibrils under appropriate conditions.
Pathogenic mutations affect fibril formation in vitro, either
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accelerating fibril formation [6, 7, 16] or resulting in
formation of fibrils that are more fragile and easier to
propagate than wild-type (WT) fibrils [61]. Moreover,
the spreading of pathological α-synuclein is closely corre-
lated with disease progression; indeed, the distribution
pattern and spread of the pathologies are useful for disease
staging of sporadic PD [3, 48]. These results suggest that
intracellular amyloid-like α-synuclein fibrils can cause PD
and DLB, and spreading of α-synuclein pathology in the
brain is considered to be the underlying mechanism of
progression of these diseases. Recently, it was experi-
mentally demonstrated that intracerebral injection of
synthetic α-synuclein fibrils and/or insoluble α-synuclein
from diseased brain converts normal α-synuclein into an
abnormal form, and the abnormal α-synuclein propagates
throughout the brain in a prion-like manner in WT
mouse [30, 33, 34, 57], α-synuclein transgenic mouse
[31, 36, 60] and monkey [44].
Common marmoset (Callithrix jacchus) is a very small
new world primate, about 25 – 35 cm in height and
300 – 500 g in weight, and is far more experimentally
tractable than macaque monkey. Since it has high fecund-
ity, with a short sexual maturation period of 18 months, it
is attracting increasing attention as an experimental model
of primates. In fact, a national project called Brain/
MINDS (Brain Mapping by Integrated Neurotechnologies
for Disease Studies) was started in 2014 in Japan to de-
velop the common marmoset as a model animal for
neuroscience [19, 38, 39]. The marmoset cortex is rela-
tively smooth, but the gyrencephalic and cortical sheet is
divided into functionally distinct cortical areas, as in Old
World monkeys [45], and thus is suitable for studies of
higher cognitive functions and social communication [11].
Therefore, marmosets are considered to be a good experi-
mental model animal to understand the evolution of brain
development and function. Moreover, transgenic marmo-
sets have already been generated, demonstrating the feasi-
bility of gene manipulation in this species [49].
To date, mouse models have been used to investigate
brain development, circuits, and higher cognitive func-
tions, but they have limitations for exploration of the
evolution and development of the primate neocortex. In
situ hybridization analysis of marmoset brain revealed
that the expression patterns of the genes that regulate
brain development (such as EphA6) are different, especially
in brain areas that have connections to the prefrontal
cortex and are presumably involved in higher cognitive
functions, although similar broad regional patterns of
expression were observed in both species [32].
A particular difference in brain development and
structure between mouse and marmoset is that striatum
of marmoset is separated into caudate nucleus and puta-
men, while these are not distinguishable in rodents. It
has been considered that caudate nucleus and putamen
were originally one structure and that they became sepa-
rated by the internal capsule during evolution [25].
Thus, the marmoset has advantageous characteristics as
an experimental animal to study brain networks, func-
tions and disease conditions.
Here, we investigated whether intracerebral injection of
α-synuclein fibrils can induce PD/DLB-like pathologies in
marmoset, and we present the first marmoset model of
α-synuclein propagation. We found that marmosets devel-
oped abundant phosphorylated α-synuclein pathologies,
similar to those observed in PD/DLB, in various brain
regions, including striatum, cortex and substantia nigra, at
only three months after injection. Remarkably, many LB-
like inclusions are observed in tyrosine hydroxylase (TH)-
positive dopamine neurons, and a significant decrease in
TH-staining was seen in the injection hemisphere. The
inclusions were also positive for fluorescent β-sheet ligands,
thioflavin-S and FSB, implying that α-synuclein deposits in
these animals should be detectable in vivo by positron
emission tomography (PET) with a suitable small-
molecular agent. Taking account of the advantages of mar-
mosets over mice, we believe the current experimental
model would be particularly useful to examine the relation-
ships between PET-detectable α-synuclein lesions and dis-
ruptions of neural networks in the absence and presence of
candidate α-synucleinopathy-modifying therapeutics.
Materials and methods
Preparation of recombinant α-synuclein and fibrils
Recombinant human and mouse wild-type α-synuclein
and fibrils were prepared as described previously [33, 57].
Briefly, purified α-synuclein (7 – 10 mg/ml) was incubated
at 37 °C in a shaking incubator at 200 rpm in 30 mM
Tris–HCl, pH 7.5, containing 0.1% NaN3, for 72 h. α-
Synuclein fibrils were pelleted by spinning the assembly
mixtures at 113,000 xg for 20 min, resuspended in 30 mM
Tris–HCl buffer (pH 7.5), and sonicated for 3 min (Biomic
7040 Ultrasonic Processor, Seiko). The protein concentra-
tions were determined by HPLC. Samples were run on
gradient 12% polyacrylamide gels and stained with Coo-
massie Brilliant Blue (CBB), or electrophoretically trans-
ferred to PVDF membranes. For immunoblotting,
membranes were incubated with 3% gelatin (Wako) for
10 min at 37 °C, followed by overnight incubation at room
temperature with primary antibodies. Next, the mem-
branes were incubated for 1 hr at room temperature with
biotinylated anti-rabbit or mouse IgG (Vector Lab), then
incubated for 30 min with avidin-horseradish peroxidase
(Vector Lab), and the reaction product was visualized by
using 0.1% 3,3-diaminobenzidine (DAB) and 0.2 mg/ml
NiCl2 as the chromogen. For electron microscopy, sam-
ples were placed on collodion-coated 300-mesh copper
grids, stained with 2% (v/v) phosphotungstate, and exam-
ined with a JEOL 1200EX electron microscope.
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Marmosets
According to animal protection considerations based on
the 3R (reduce, reuse, recycle) principle, we designed the
experiment very carefully to minimize the number of
animals used. Two female 26-month-old marmosets
(individual recognition No. 14H and 14I; born on 4th
April, 2014 and bred at the Animal Research Division,
Tokyo Metropolitan Institute of Medical Science) were
used for this experiment.
Stereotaxic surgery
The marmosets were anesthetized with Ketamine Hydro-
chloride (20–40 mg/kg i.m.) and Xylazine (0.05 mg/kg
i.m.), and Butorphanol (0.05–0.1 mg/kg i.m.). Then, 50 μL
aliquots of 4 mg/mL mouse α-synuclein fibrils were
injected into both caudate nucleus (interaural +9.5 mm,
Lateral 3 mm, Depth 6 mm) and putamen (interaural
+9.5 mm, Lateral 6 mm, Depth 3 mm) in the right hemi-
sphere of 14H brain (total 400 μg). A 50 μL aliquot was
injected into caudate nucleus (interaural +9.5 mm, Lateral
3 mm, Depth 6 mm) in the right hemisphere of 14I brain
(total 200 μg). The marmosets were bred for 3 months
after injection in a biological safety level 2 (BSL-2) envir-
onment. All experimental protocols were approved by the
Animal Care and Use Committee of Tokyo Metropolitan
Institute of Medical Science (No. 16038).
Antibodies
Primary antibodies used in this study are listed in Table 1.
An anti-phosphorylated α-synuclein rabbit monoclonal
antibody to pS129 (Abcam) and other anti-α-synuclein
antibodies, including LB509 [26] (a gift from Dr
Iwatsubo), 75–91 (Cosmo bio), 131–140 (Cosmo bio)
and #2642 (Cell Signaling Technology) were used for
detection and characterization of α-synuclein pathologies
in marmoset brains. Anti-p62 (Progen), anti-Ub (Dako,
Millipore), anti-TH (Millipore), anti-NeuN (Millipore),
anti-GFAP (Sigma), anti-CNPase (Abcam) and anti-Iba1
(Wako) antibodies were also used.
Immunohistochemistry
Marmosets were deeply anesthetized with pentobarbital
injection and killed, and the brain was perfused with
0.1 M phosphate buffer, followed by 10% formalin neutral
buffer solution. After fixation, whole brains were sectioned
coronally at 50 μm using a vibratome (Leica, Wetzlar,
Germany). For high-sensitivity detection, free-floating
brain sections were treated with formic acid for 20 min,
washed, and boiled at 100 °C for 20 min as described [33].
Sections were then incubated with 0.5% H2O2 in methanol
for 30 min to inactivate endogenous peroxidases, blocked
with 10% calf serum in PBS for 20 min, and incubated
overnight with appropriate antibodies. After incubation
with the biotinylated secondary antibody for 2 h, labeling
was detected using the ABC staining kit (Vector) with
DAB. Sections were counterstained with hematoxylin.
Slides were coverslipped with mounting medium. Images
were observed with an all-in-one microscope/digital
camera (BZ-X710; Keyence).
For double-label immunofluorescence detection, brain
sections were pretreated as described above and incubated
overnight at 4 °C with a cocktail of appropriate primary
antibodies. The sections were washed and incubated with
a cocktail of Alexa568-conjugated goat anti-mouse or
anti-rabbit IgG and Alexa488-conjugated goat anti-mouse
or anti-rabbit or anti-guinea pig IgG (Molecular Probes).
After further washing, the sections were coverslipped with
Table 1 Antibodies used in this study
Primary antibodies Type Source Dilution
pS129 (phosphorylated a-syn) rabbit mono Abcam (ab51253) 1:2000
LB509 (human a-syn) mouse mono Gift from Dr Iwatsubo 1:1000
75–91 (a-syn 75–91) rabbit poly Cosmo bio (CAC-TIPSNP08) 1:1000
131–141 (a-syn 131–140) rabbit poly Cosmo bio (CAC-TIPSNP09) 1:1000
#2642 (a-syn) rabbit poly Cell Signaling Tech (#2642) 1:1000
Anti-p62 guinea pig poly Progen (GP62-C) 1:1000
Anti-Ub rabbit poly Dako (Z0458) 1:1000
Anti-Ub mouse mono Millipore (MAB1510) 1:1000
Anti-TH rabbit poly Millipore (AB152) 1:1000
Anti-TH mouse mono Millipore (MAB318) 1:1000
Anti-NeuN mouse mono Millipore (MAB377) 1:1000
Anti-GFAP mouse mono Sigma (G3893) 1:1000
Anti-CNPase mouse mono Abcam (ab6319) 1:200
Anti-Iba1 rabbit poly Wako (016–20001) 1:1000
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non-fluorescent mounting media (VECTASHIELD;
Vector Laboratories) and observed with the BZ-X710.
To measure positive cells, 7–9 sections of substantia
nigra were randomly selected, and all images were cap-
tured with BZ-X710 microscope using the same settings.
The areas of pS129-positive cells and TH-positive cells
in the right and left substantia nigra were extracted and
quantified by BZ-H3C Hybrid Cell Count Software
(Keyence).
Thioflavin-S and FSB stainings
Thioflavin-S and FSB [23, 50] were purchased from
Sigma-Algrich and Dojindo, respectively. For fluorescence
labeling with β-sheet ligands, thioflavin-S and FSB, brain
sections were mounted on a glass slide and dried with
warm air. Sections were incubated in 20% ethanol con-
taining 0.001% β-sheet ligands at room temperature for
30 min. The samples were rinsed with 20% ethanol for
5 min, dipped into distilled water twice for 3 min each,
and mounted in VECTASHIELD. Fluorescence images
were captured using a BZ-X710 fluorescence microscope
equipped with Filter set ET-ECFP (Chroma Technology)
for thioflavin-S and FSB. After fluorescence microscopy,
all sections labeled with ligands were autoclaved for anti-
gen retrieval, immunostained with the pS129 antibody,
and examined using the BZ-X710 instrument.
Results
Inoculation of mouse α-synuclein fibrils into marmoset brain
Marmoset α-synuclein, mouse α-synuclein and human
α-synuclein share 96 – 97% amino acid sequence hom-
ology (Fig 1), but marmoset and mouse α-synuclein pro-
teins both have a threonine residue at amino acid
position 53, which is an aggregation-prone mutation in
familial Parkinson’s disease [41]. Therefore, we used
mouse α-synuclein fibrils instead of human α-synuclein
fibrils for injection into marmoset brains in this experi-
ment. This had the advantage that we could investigate
whether endogenous marmoset α-synuclein is deposited
in brains injected with mouse α-synuclein fibrils, be-
cause the two can be distinguished with antibodies such
as LB509. Recombinant mouse α-synuclein and the fibrils
were prepared as described, and images of purified recom-
binant mouse α-synuclein and the fibrils are shown in
Fig 2. EM pictures of the injected sample showed that
most of the fibrils were straight, 5 – 10 nm in width, and
50 – 300 nm in length (Fig 2C). The prion-like seeding
activity of the fibrils to convert normal α-synuclein into
abnormal form was checked in our cultured cell model
[37] and mouse model [57] (data not shown). We injected
200– 400 μg of the α-synuclein fibrils; this amount was
chosen based on the amount used in the previous mouse
experiments (10 μg fibrils/0.3 g mouse brain vs 200 μg
fibrils/7 g marmoset brain).
PD-like pathologies in marmoset brain within only
3 months after injection
Three months after injection, formalin-fixed marmoset
brain sections were prepared and immunostained with
anti-phospho-Ser129 of α-synuclein (pS129). Surprisingly,
abundant pS129-positive structures were observed
throughout the brain regions, including the injection
sites in the caudate nucleus and putamen, accumbens,
bed nucleus of the stria terminalis, substantia nigra, amyg-
dala, a wide region of cortex, thalamus, globus pallidus,
dorsal raphe nuclei, raphe nucleus and hippocampal CA1
in both marmosets (Fig 3). These abnormal α-synuclein
pathologies were also positive with other anti-α-synuclein
antibodies (Fig 4), including LB509. The results indicated
that endogenous marmoset α-synuclein is converted into
Fig. 1 Comparison of amino acid sequences of human (Homo sapiens), marmoset (Callithrix jacchus) and mouse (Mus musculus) α-synuclein. Amino
acids in human α-synuclein that differ from those of marmoset and mouse α-synuclein are indicated in red, while amino acids in marmoset and mouse
α-synuclein that differ from those in human α-synuclein are indicated in green and blue, respectively. Epitopes of α-synuclein antibodies used in this
study are also indicated
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an abnormal form by inoculation of mouse α-synuclein fi-
brils and deposited in the brain. Most of the inclusions
were also positive for antibodies to ubiquitin and p62
(Fig 5), as is the case in the brains of patients. Labeling of
the inclusions with these antibodies was observed without
pretreatment of sections with formic acid and boiling, but
the specificity and sensitivity were both increased by the
pretreatment (data not shown).
α-Synuclein propagated retrogradely through neuronal
networks
The distributions of the pathologies were similar in these
two marmosets 14H and 14I, although more abundant
and severe pathologies were observed in the marmoset
14H (Fig 6), in which α-synuclein fibrils were injected at
both caudate nucleus and putamen. The α-synuclein
pathologies were robust in the injected right hemisphere,
but also present in the left hemisphere, although to a
much lesser extent than in the right hemisphere (Fig 6).
The spreading of α-synuclein pathology observed in the
marmosets seemed consistent with propagation through
neuronal networks (Brainstem anatomy WIKI, http://
brainstemwiki.colorado.edu/doku.php/start). In these mar-
mosets, α-synuclein pathologies were seen from the injec-
tion sites (caudate nucleus and putamen) to neocortex,
substantia nigra, amygdala, globus pallidus and thalamus,
which are brain nuclei or regions providing direct input to
striatum. As projections to the striatum, nigrostriatal input,
corticostriatal input, thalamostriatal input, and inputs from
the external segment of globus pallidus and subthalamic
nucleus have been reported [4, 12–14, 20, 40, 53, 59].
Therefore, pathological α-synuclein seemed to have spread
to the second connection regions from the direct input
regions over the 3-month period. Overall, the spreading
pattern of pathological α-synuclein seemed to be the
same as in mouse brain [30, 33, 57], and was consistent
with the spreading pattern of retrograde tracers [40].
It is noteworthy that abundant LB-like round pS129-
positive inclusions were detected in substantia nigra of
these marmosets (Fig 3, 4, 5 and 7). The nigral LB-like
inclusions were more prominent in the marmoset injected
into both caudate nucleus and putamen than in the
marmoset injected only into caudate nucleus. Double
labeling of the inclusions with anti-tyrosine-hydroxylase
(TH) antibody confirmed that the inclusions are formed in
TH-positive dopaminergic neurons (Fig 7b, c), indicating
that pathological α-synuclein was propagated retrogradely
from striatum to nigral neurons.
Degeneration of dopaminergic neurons with pS129-
positive inclusions
Macroscopical observation of sections stained with anti-TH
antibody indicated an apparent decrease of TH-positive
staining in the injected hemisphere (Fig 7a). Therefore, we
quantitated TH-positive neurons in the right and left
hemispheres and we also quantitated pS129-positive
neurons, and compared them. As shown in Fig 7d – e,
pS129-positive aggregates were much more abundant
in the right hemisphere than in the left hemisphere. On
the other hand, a significant decrease in the amount of
TH-positive neurons was detected in the right hemi-
sphere in both marmosets, although the reduction was
more prominent in the marmoset that developed more
pS129-positive aggregates following injection into both
caudate nucleus and putamen.
Fig. 2 Characterization of purified mouse α-synuclein and fibrils. a, purified monomeric human α-synuclein (lane 1), mouse α-synuclein (lane 2)
and mouse α-synuclein fibril (lane 3) samples were analyzed by CBB staining (0.5 μg of protein/lane). b, results of immunoblotting with anti-α-synuclein
antibodies (131–140 and LB509) (B, 0.01 μg of protein/lane). c, electron microscopy of α-synuclein fibrils injected into marmoset brains in this
study. Negatively stained short fibrils, 50 –300 nm in length, were observed. Scale bar: 100 nm
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Most of the aggregates are strongly positive for both FSB
and thioflavin-S
To further investigate whether the pS129-positive ag-
gregates in these marmosets are amyloid-like struc-
tures, we tried to stain them with thioflavin S and FSB.
Remarkably, most of these aggregates, including LB-like
and LN-like structures, were strongly positive for both
thioflavin-S and FSB (Fig 8), indicating that the inclu-
sions formed in marmosets at only 3 months after in-
jection have cross-β structures similar to those found
in brains of patients. These results suggest that propa-
gation and spreading of these α-synuclein pathologies
in vivo may be monitored by the use of amyloid-
imaging probes.
Fig. 4 Immunostainings of 14H brain sections with anti-α-synuclein antibodies (LB509-positive inclusions in substantia nigra and stainings with
75–91 and #2642 in caudate nucleus). Similar inclusions were observed in 14I marmoset brain. Scale bars: 50 μm
Fig. 3 Immunostainings of 14H brain sections with anti-pS129 antibody. PS129-positive inclusions observed in various brain regions. Cd: caudate
nucleus, Pu: putamen, Acb: accumbens, ST: bed nucleus of the stria terminal, SNC: substantia nigra compacta, SNR: substantia nigra pars reticulata,
Amy: amygdala, Thal: thalamus, Cing cx: cingulate cortex, Ins cx: insular cortex, Ent cx: entorhinal cortex, Temp cx: temporal cortex, DR: dorsal raphe
nuclei, LC: locus ceruleus, CA1: hippocampal CA1, EGP: external segment of globus pallidus. Similar pS129-positive inclusions were also observed in 14I
marmoset brain. Scale bars: 50 μm
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Degenerating neurons with α-synuclein inclusions may be
cleared by microglial cells
All of the inclusions seemed to be neuronal aggregates,
and no astrocytic or oligodendrocytic glial inclusions
were observed. In fact, most of the pS129-positive inclu-
sions were closely associated with NeuN-positive nuclei
in neuronal cells, but no such colocalization was ob-
served with astrocytic marker GFAP or oligodendrocytic
marker CNPase (Fig 9a, b and c). Very interestingly,
double labeling with LB509 and Iba1 revealed that some
of the LB509-positive inclusions were colocalized with
Iba1-positive microglial cells (Fig 9d, e), strongly sug-
gesting that the inclusions or degenerating neurons with
aggregates may be phagocytosed by microglial cells. The
LB509-positive α-synuclein inclusions should be composed
of endogenous marmoset α-synuclein, but not injected
mouse α-synuclein, since LB509 recognizes human and
primate α-synuclein. The colocalization was confirmed by
3D imaging (Fig 9e). Similar colocalization of α-synuclein
inclusions and microglial cells was observed by double
labeling with anti-pS129 and anti-Iba1 antibodies (data not
shown).
Discussion
Emerging evidence indicates that intracellular amyloid-like
proteins have prion-like properties and propagate from cell
to cell by converting normal proteins into abnormal forms
[18, 22, 27, 42]. This prion-like propagation may account
for the characteristic spreading of pathological proteins
including α-synuclein, tau and TDP-43, and also for
disease progression in major neurodegenerative diseases
with these protein pathologies, such as Parkinson’s disease,
Alzheimer’s disease and amyotrophic lateral sclerosis.
In this study, we tested whether inoculation of synthetic
mouse α-synuclein fibrils can induce PD-like α-synuclein
pathologies and prion-like propagation in two adult
marmosets by injecting the fibrils into striatum (one
animal was injected into caudate nucleus and the other,
into caudate nucleus and putamen). Within only 3 months
after injection, we observed abundant phospho-α-synuclein
Fig. 5 Immunostainings of 14H brain sections (substantia nigra) with anti-p62 and anti-ubiquitin (anti-Ub) antibodies. Diaminobenzidine staining
(upper panel) and double immunofluorescence stainings (middle and lower panel) indicated colocalization of pS129-positive inclusions and p62
or ubiquitin. Similar results were obtained in other brain regions and also in 14I marmoset brain. Scale bars: 50 μm
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pathologies in various brain regions of both marmosets, in-
dicating that prion-like conversion readily occurred in the
primate brains even within this short time-scale. Luk et al.
and we have established a propagation model in wild-type
mouse [30, 33, 34, 57], but others have found it difficult to
detect the pathologies in wild-type mouse [46]. It has also
been reported that intranigral or intrastriatal inoculations
of PD-derived LB extracts in monkey resulted in pro-
gressive nigrostriatal neurodegeneration, but clearly de-
fined LB-type inclusions were not observed [44]. The
results of the present study clearly demonstrate that in-
oculation of fibrillar α-synuclein in striatum of wild-
type marmoset triggered PD-like α-synuclein patholo-
gies, which propagated retrogradely to substantia nigra
and other input regions, and induced degeneration of
dopaminergic neurons. Furthermore, most of the inclu-
sions were positive for amyloid-sensitive dyes, such as
thioflavin-S and FSB. This simple experiment has provided
direct evidence for prion-like propagation of pathological
α-synuclein in brains of primates, and the model should
be very useful for establishing in vivo imaging method-
ology for abnormal α-synuclein propagation and for de-
velopment and evaluation of disease-modifying drugs
for α-synucleinopathies.
Fig. 6 Distribution of pS129-positive α-synuclein pathologies at 3 months after mouse α-synuclein fibril injection in the two marmosets (14H and 14I).
The pS129-positive phase contrast images of four coronal brain sections (a – d) acquired by using BZ-X710 microscope system are shown in red with
marmoset brain sections of corresponding brain regions. Coronal brain atlas (Hardman and Ashwell, 2012) locations of interaural +12.35 mm
(a), +10.80 mm (b), +07.70 mm (c) and +05.60 mm (d) are shown. Asterisks in b indicate the injection sites in caudate nucleus and/or putamen. Arrows
in d indicate substantia nigra
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Fig. 7 (See legend on next page.)
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In this study, we did not perform behavioral tests, but
we did not observe any apparent symptoms or behavior
deficits in these marmosets, suggesting that they may
not develop strong phenotypes within 3 months after in-
oculation. It is reasonable to speculate that motor defi-
cits would only be detected after the loss of more than
50% of dopamine neurons, as is the case in PD patients.
We observed 20 – 40% decrease of TH-positive cells in
the right hemisphere in the animals in this study. Further
studies will be needed to establish the relationship be-
tween pathologies and symptoms in wild-type marmosets.
The present model should be useful for research on
PD and α-synucleinopathies, because this is a primate
and non-transgenic wild-type animal model, which would
not suffer from various artifacts associated with overex-
pression of proteins in transgenic animals [47] or the use
of viral vector-mediated gene transfer systems. Among
mouse models, Tg-mice overexpressing human A53T
mutant α-synuclein (such as M83 line) are considered a
good host animal for inoculation experiments, because
disease symptoms and α-synuclein pathologies appear at
about ~100 days after inoculation [43]. When Tg-marmoset
models overexpressing human α-synuclein are available,
it will be interesting to inject synthetic α-synuclein fi-
brils or brain extracts from patients into these animals
to see whether the appearance of PD-like symptoms or
pathologies is accelerated.
By double immunolabeling of marmoset brain sections
with LB509 and Iba1, we demonstrated that some of the
α-synuclein inclusions are colocalized with Iba1-positive
microglial cells. This finding suggests that inclusions or
degenerating neurons with aggregates may be phagocy-
tosed by microglial cells. Although it has been debated
whether inflammation constitutes a cause or consequence
(See figure on previous page.)
Fig. 7 Presence of pS129-positive inclusions in TH-positive neurons and significant reduction of TH-positive neurons in the ipsilateral side of
the marmosets (14H and 14I). a, Immunohistochemical staining of substantia nigra with anti-TH antibody and diaminobenzidine staining in
14H. b, Double-labeling of substantia nigra with anti-TH (green) and anti-pS129 (red) antibodies in 14H. c, High magnification of the double-labeling
of substantia nigra on the ipsilateral side (indicated by the squares in b). An apparent reduction of TH-positive dopamine neurons was de-
tected in the ipsilateral side of the brain compared to the contralateral side. Areas of pS129-positive inclusions and areas of TH-positive neu-
rons were quantified (d – g). d, e Quantification of pS129-positive inclusions and TH-positive cells in the right and left hemispheres of 14H
brain. f, g Quantifications of pS129-positive inclusions and TH-positive cells in the right and left hemispheres of the 14I. To measure positive
cells, 7– 9 sections (the numbers are indicated in the columns) were selected. Larger amounts of pS129-positive inclusions were detected and
significant reductions of TH-positive neurons were detected in the ipsilateral sides of substantia nigra of the two marmosets. Data were analyzed by
Student's t-test. All error bars indicate means ± S.E.M. **p < 0.002, * p < 0.05. Scale bars: 50 μm
Fig. 8 Fluorescence labeling of α-synuclein inclusions with β-sheet ligands in 14H (caudate nucleus). a Double staining with 0.001% thioflavin-S
(left) and anti-pS129 antibody (middle). Top right and bottom right panels depict high-power photomicrographs of areas indicated by squares in
the left and middle panels, respectively. A large proportion of α-synuclein inclusions stained with pS129 was labeled with thioflavin-S. b Double
staining with 0.001% FSB (left) and pS129 (middle). Top right and bottom right panels depict high-power photomicrographs of areas indicated by
the squares in the left and middle panels, respectively. A large proportion of α-synuclein inclusions stained with pS129 was strongly labeled with
FSB. Similar labelings were observed in 14I marmoset brain. Scale bars: 50 μm
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Fig. 9 Double immunolabeling of α-synuclein inclusions with pS129 antibody and anti-NeuN, anti-GFAP, anti-CNPase or anti-Iba1 antibodies in
14H (caudate nucleus) a Double staining with anti-pS129 and anti-NeuN antibodies. b Double staining with anti-pS129 and anti-GFAP antibodies.
c Double staining with pS129 and anti-CNPase antibodies. d Double staining with LB509 and anti-Iba1 antibodies. e, A high-power photomicrographs
of the double staining with LB509 and anti-Iba1 antibodies. Similar stainings were observed in various other brain regions and also in 14I marmoset
brain. Scale bars: 50 μm
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of PD, increasing evidence suggests that microglial cells
and inflammatory pathways are involved in the pathogen-
esis and progression of PD [8, 9]. Indeed, activated micro-
glia are prevalent in the most pathologically affected areas
in the brains of PD patients [9, 35]. Recent studies also
demonstrated that toll-like receptor 2 may contribute to
α-synuclein pathology in PD [10]. However, there has
been no direct evidence that microglial cells are involved
in the clearance of α-synuclein aggregates, and our
findings here represent the evidence that α-synuclein
aggregates or cells with inclusions are phagocytosed by
microglial cells for clearance. It seems plausible that
such microglial phagocytosis of α-synuclein inclusions
may be a protective event to clear degenerating neurons
and reduce inflammation in the brain, but further studies
will be needed to confirm this. Our marmoset model
should be useful for elucidating the molecular mecha-
nisms of α-synuclein propagation, and also for exploring
neuronal circuits in marmoset brain and human brain.
Conclusions
Intracerebral injection of synthetic α-synuclein fibrils
into adult wild-type marmoset brains induced abundant
α-synuclein pathologies within only three months after
injection. Most of the α-synuclein inclusions were posi-
tive for β-sheet ligands (thioflavin-S and FSB). Remark-
ably, robust Lewy body-like inclusions were formed in
TH-positive neurons and a significant decrease in the
numbers were observed, strongly suggesting the retro-
grade spreading of abnormal α-synuclein and the neuro-
toxicity. Furthermore, we provide evidence indicating
that neurons with abnormal α-synuclein inclusions may
be cleared by microglial cells. This is the first marmoset
model for α-synuclein propagation, and it should be use-
ful for elucidating the molecular mechanisms of α-
synuclein propagation, and also for exploring neuronal
circuits in marmoset brain and human brain.
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